Labcorp Reports Strong Q4 2025 Earnings Amid Divergent Biopharma Trends

Labcorp Holdings Inc. (NYSE: LH) concluded fiscal year 2025 with a robust fourth-quarter performance that highlighted the resilience of its core diagnostics business and the strategic efficiency of its LaunchPad initiative. The company reported quarterly revenue of $3.5 billion, a 5.6% increase year-over-year, which contributed to a full-year growth rate exceeding 7%. Perhaps most impressive to analysts was the bottom-line expansion; adjusted earnings per share (EPS) surged 18% in the quarter to $4.07, significantly outpacing revenue growth and signaling a high degree of operational leverage.

The Diagnostics segment remains the primary engine of Labcorp's growth. Revenue in this division rose 5.5% to $2.7 billion, supported by a healthy mix of organic growth (4.1%) and strategic acquisitions (1.5%). Total volume increased by 2.2%, while price and mix contributed a 3.3% tailwind. This segment also saw a substantial 150 basis point improvement in adjusted operating margins, a testament to the company's ability to manage costs while scaling its testing capabilities. CEO Adam Schechter noted that the demand for specialized testing continues to outpace routine diagnostics, a trend that typically carries higher margins and stickier customer relationships.

“

Revenue in this division rose 5.5% to $2.7 billion, supported by a healthy mix of organic growth (4.1%) and strategic acquisitions (1.5%).

However, the Biopharma Laboratory Services (BLS) segment presented a more complex narrative, characterized by a sharp divergence between late-stage and early-stage research activities. Overall BLS revenue grew a modest 3.4% to $793 million, but this figure masks significant internal volatility. The Central Laboratory business, which supports large-scale clinical trials, saw revenue jump 11.1% (7.7% on a constant currency basis). In stark contrast, the Early Development segment experienced a 13.5% decline, dropping 15.1% when adjusted for currency. This decline reflects a broader industry-wide cooling in early-stage biotech funding and a strategic shift by pharmaceutical giants to prioritize late-stage assets over riskier, early-phase discovery work.

Despite the headwinds in Early Development, Labcorp’s forward-looking indicators remain positive. The company reported a trailing twelve-month book-to-bill ratio of 1.09 for the entire enterprise, with the BLS segment specifically posting a quarterly book-to-bill of 1.16. This suggests that the pipeline for future clinical trial support remains healthy and that the company is successfully replacing completed contracts with new business. CFO Julia Wang emphasized that the company’s disciplined capital allocation strategy remains a priority, with $258 million deployed toward acquisitions in the quarter and $225 million returned to shareholders via stock repurchases.